Samer Al Hadidi, MD,MS,FACP
@HadidiSamer
Associate Professor @UAMSMyeloma. Alumni heme/onc @bcmhouston, clinical research/biostat @UMich.Focus on plasma cell disorders & health disparities
Myeloma is a curable malignancy #mmsm Yes it is curable The cure rate is not ideal (not all/most patients are cured)- there is still work to be done to improve We estimate that one out of three patients with standard risk myeloma (vast majority of cases) are cured 🧵
Check our recent work @UAMSMyeloma published @BloodAdvances : Prognostic Impact of Focal Lesion Location and Persistence in Multiple Myeloma: Insights from Serial PET/DWI Imaging #mmsm ➡️ashpublications.org/bloodadvances/… n= 243 multiple myeloma patients followed 9.9 years with serial…
Important insights into teclistamab in secondary plasma cell leukemia (sPCL) from @asis_shr & team: 🧬 ORR 31% (vs ~63% in MM) 🧬 Prior BCMA exposure = no response 🧬 Responders: median PFS 4.6 mo 🧬 Non-responders: PFS 18 days, OS ~1 mo 🧬 No grade 3–4 CRS Tough disease. We need…
Check our recent work @BloodAdvances @UAMSMyeloma led by @asis_shr #mmsm The Efficacy of Teclistamab in Multiple Myeloma Patients with Secondary Plasma Cell Leukemia ➡️n=16 sPCL, ORR: 31% (lower than typical MM ORR ~63%) ➡️Prior BCMA exposure = no response - all 4 patients with…
🧵Teclistamab in Secondary Plasma Cell Leukemia (sPCL): A First Look New data from @HadidiSamer @UAMSMyeloma offers the first insights into this bispecific’s use in sPCL — a rare, aggressive multiple myeloma variant. Here’s what clinicians need to know 👇 #mmsm #MedEd #myeloma…
Check our recent work @BloodAdvances @UAMSMyeloma led by @asis_shr #mmsm The Efficacy of Teclistamab in Multiple Myeloma Patients with Secondary Plasma Cell Leukemia ➡️n=16 sPCL, ORR: 31% (lower than typical MM ORR ~63%) ➡️Prior BCMA exposure = no response - all 4 patients with…
Check our recent @UAMSMyeloma work #mmsm Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma ➡️ journals.sagepub.com/doi/10.1177/18… 👇
#mmsm @US_FDA ODAC Blenrep Voting results Yes: 1 No: 7 Is the overall benefit-risk of Blenrep in combination with pomalidomide and dexamethasone favorable at the proposed dosage in the proposed patient population ?
#mmsm @US_FDA ODAC Blenrep Voting results Yes: 3 No: 5 Is the overall benefit-risk of Blenrep in combination with bortezomib and dexamethasone favorable at the proposed dosage in the proposed patient population ?
Negative trial for Anselamimab in AL amyloidosis #mmsm ➡️ astrazeneca.com/media-centre/p… ✅Daratumumab was permitted (not required) as part of ttt regimen,~ 80% of patients got daratumumab as part of their ttt 🛑press release with improvement in certain subgroups (not defined)…
Great connecting with so many incredible hematologists and the amazing @ASH_hematology team emphasizing #Fight4Hematology! Grateful for the inspiring discussions on advancing care for patients and supporting those treating blood disorders. 💪🩸 #Hematology #PatientCare…
ASH Committee on Communications Summer 2025 meeting complete! Energized to strengthen our Fight4Hematology campaign & advocacy efforts protecting federal funding for hematology research. The future of hematology care depends on continued innovation. #ASH #Fight4Hematology
Join @HealthTree Webinar: Can You Stop Myeloma Treatment and Still Stay in Remission? #mmsm @UAMSMyeloma 🕣 Jul 29, 2025 / 01:00PM - 02:00PM EDT ➡️ healthtree.org/myeloma/commun… Will be sharing some long term data as well as if this is possible, there will be room for questions…
I have been following @VincentRK and @HadidiSamer to keep up with #IMWG25 data! Here 👇 is the high risk MM! x.com/vincentrk/stat…
Just out! New IMS/ IMWG Definition of High Risk Myeloma. @JCO_ASCO #IMWG25 @Myeloma_Society @IMFmyeloma @NikhilMunshiMD @mvmateos @SagarLonialMD @szusmani @NoopurRajeMD
Genomic Staging for High risk MM: - At least one of these abnormalities: 1. del(17p), with a cutoff of >20% clonal fraction, and/orTP53 mutation 2. IgH translocation including t(4;14), t(14;16), or t(14;20) along with 1q+ and/or del(1p32) 3. Monoallelic del(1p32) along with…
International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma | @JCO_ASCO ascopubs.org/doi/full/10.12…
x.com/HadidiSamer/st…
Check our long term follow up of earlier total therapy protocols in Arkansas @JAMAOnc @UAMSMyeloma #mmsm ➡️ jamanetwork.com/journals/jamao… ✅ With time limited therapy&median follow up of ~17 years of 1202 patients, we estimate one out of three patients are cured from their multiple…
Presentation from @HadidiSamer at #ASCO25. #uamsmyeloma #uamscancer #WPRCI #uamshealth #mmsm
#mmsm #ASCO25 Per request, here I provide slides of the educational talk: What is the current state of induction with four drug therapy? 🧵 @UAMSMyeloma